COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?
https://doi.org/10.22416/1382-4376-2022-32-2-85-92
Abstract
The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic.
Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells; virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota.
Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases.
Supporting agencies: Publication was supported by “Materia Medica”.
About the Author
V. A. Akhmedov
Omsk State Medical University
Russian Federation
Russian Federation
Vadim A. Akhmedov — Dr. Sci. (Med.), Prof., Head of the Chair of Medical Rehabilitation of Additional Professional Education
644099, Omsk, Lenina str., 12
References
1. Munster V.J., Feldmann F., Williamson B.N., van Doremalen N., Perez-Perez L., Schulz J., et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. 2020;585(7824):268–72. DOI: 10.1038/s41586-020-2324-7
2. Hamid S., Mir M. Y., Rohela G.K. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679. DOI: 10.1016/j.nmni.2020.100679
3. D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020;18(8):1663–72. DOI: 10.1016/j. cgh.2020.04.001
4. Ianiro G., Mullish B.H., Kelly C.R., Sokol H., Kassam Z., Ng S.C., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5(5):430–2. DOI: 10.1016/S2468-1253(20)30082-0
5. Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome — An Update. Front Psychiatry. 2020;11:664. DOI: 10.3389/fpsyt.2020.00664
6. Klem F., Wadhwa A., Prokop L.J., Sundt W.J. Farrugia G., Camilleri M., et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152:1042–54. DOI: 10.1053/j.gastro.2016.12.039
7. Ghoshal U.C., Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011;26 (Suppl 3):94–101. DOI: 10.1111/j.1440-1746.2011.06643.x
8. Schmulson M., Ghoshal U.C., Barbara G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. Am J Gastroenterol. 2021;116:4–7. DOI: 10.14309/ajg.0000000000001062
9. Ghoshal U.C., Ghoshal U., Mathur A., Singh R.K., Nath A.K., Garg A., et al. The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome. Clin Transl Gastroenterol. 2020;11:e00259. DOI: 10.14309/ ctg.0000000000000259
10. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20. DOI: 10.1128/JVI.00127-20
11. Wong M.C., Huang J., Lai C., Ng R., Chan F.K., Chan P.K. Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis. J Infect 2020;81:e31–8. DOI: 10.1128/JVI.00127-20
12. Cardinale V., Capurso G., Ianiro G., Gasbarrini A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. Dig Liver Dis. 2020;52:1383–9. DOI: 10.1016/j.dld.2020.09.009
13. Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI: 10.1177/1756284821993586
14. Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired postinfectious irritable bowel syndrome. Gut. 2003;52(4):523–6. DOI: 10.1136/gut.52.4.523
15. Downs I.A., Aroniadis O.C., Kelly L., Brandt L.J. Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease. J Clin Gastroenterol. 2017;51:869–77. DOI: 10.1097/MCG.0000000000000924
16. Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G. , Garg A.X., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13. DOI: 10.1053/j.gastro.2009.12.049
17. Tang H.Y., Jiang A.J., Wang X.Y., Wang H., Guan Y.Y., Li F., et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187. DOI: 10.21037/atm-21-2779
18. Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology 2019;156(1):46–58. DOI: 10.1053/j.gastro.2018.07.011
19. Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085. DOI: 10.1155/2012/151085
20. Ong J., Young B.E., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69:1144–5. DOI: 10.1136/gutjnl-2020-321051
21. Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–78. DOI: 10.1093/cid/ciaa709
22. Rodrigues P.B., Dos Santos Pereira Gomes A.B., Genaro L.M., Pascoal L.B., de Souza A.P., Leal R.F. Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? Adv Exp Med Biol. 2021;1327:93–106. DOI: 10.1007/978-3-030-71697-4_7
23. Tian Y., Sun K.Y., Meng T.Q., Guo S.M., Li G.M., Xiong G.L., et al. Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery. Front Nutr. 2021;8:638825. DOI: 10.3389/fnut.2021.638825
24. Gaibani P., D’Amico F., Bartoletti M., Lombardo D., Rampelli S., Fornaro G., et al. The Gut Microbiota of Critically Ill Patients With COVID-19. Front Cell Infect Microbiol. 2021;11:670424. DOI: 10.3389/fcimb.2021.670424
25. Sokol H., Contreras V., Maisonnasse P., Desmons A., Delache B., Sectio V., et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes. 2021;13(1):1–19. DOI: 10.1080/19490976.2021.1893113
26. Chen J., Hall S., Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1–13. DOI: 10.1002/rmv.2211
27. Zhou Y., Zhang J., Zhang D. Ma V.L., Wang X., et al. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. Microbiol. 2021;59(10):941–8. DOI: 10.1007/s12275-021-1206-5
28. Yamamoto S., Saito M., Tamura A., Prawisuda D, Mizutani T., Yotsuyanagi H. The human microbiome and COVID-19: A systematic review. PLoS One. 2021;16(6):e0253293. DOI: 10.1371/journal.pone.0253293
29. Zuo T., Zhang F., Lui G.C., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020;159:944–55.e8. DOI: 10.1053/j.gastro.2020.05.048
30. Cardinale V., Capurso G., Ianiro G., Gasbarrin A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis. 2020;52(12):1383–9. DOI: 10.1016/j.dld.2020.09.009
31. Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69:1543–4. DOI: 10.1136/gutjnl-2020-321388
32. Quek S.X.Z., Loo E.X.L, Demutska A, Chua C.E., Kew G.S., Wong S., et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021;36(8):2187–97. DOI: 10.1111/jgh.15466
33. Nam Y., Kwon S.C., Lee Y.J., Jang E.C., Ahn S.H. Relationship between job stress and functional dyspepsia in display manufacturing sector workers: a cross-sectional study. Ann Occup Environ. Med. 2018;30:62. DOI: 10.1186/s40557-018-0274-4
34. Felstead A., Henseke G. Assessing the growth of remote working and its consequences for effort, well-being and work-life balance. New Technol Work Employ. 2017;32(3):195–212. DOI: 10.1111/ntwe.12097
35. Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346
36. Scarmozzino F., Visioli F. Covid-19 and the subsequent lockdown modified dietary habits of almost half the population in an Italian sample. Foods 2020;9(5):675. DOI: 10.3390/foods9050675
37. Hislop T.G., Bajdik C.D., Balneaves L.G., et al. Physical and emotional health effects and social consequences after participation in a low-fat, high-carbohydrate dietary trial for more than 5 years. J Clin Oncol. 2006;24(15):2311–7. DOI: 10.1200/JCO.2005.04.3042
38. Liese A.D., Weis K.E., Pluto D., Smith E., Lawson A. Food store types, availability, and cost of foods in a rural environment. J Am Diet Assoc. 2007;107(11):1916–23. DOI: 10.1016/j.jada.2007.08.012
39. Barrett J.S. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28(3):300–6. DOI: 10.1177/0884533613485790
40. Coroiu A., Moran C., Campbell T., Geller A.C. Barriers and facilitators of adherence to social distancing recommendations during COVID-19 among a large international sample of adults. PLoS One. 2020;15:e0239795. DOI: 10.1371/journal.pone.0239795
41. Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medicine (Baltimore). 2020;99(51):e23711. DOI: 0.1097/MD.0000000000023711
42. Conte L., Toraldo D.M. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI: 10.1177/1753466620937170
43. Mehtab W., Agarwal A., Singh N., Malhotra A., Makharia G.K. All that a physician should know about FODMAPs. Indian J Gastroenterol 2019;38:378–90. DOI: 10.1007/s12664-019-01002-0
44. Ghoshal U.C. Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: pros. J Neurogastroenterol Motil. 2017;23:334–40. DOI: 10.5056/jnm17020
45. Zhang Q., Yue S., Wang W., Chen Y., Zhao C., Song Y., et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785–803. DOI: 10.1142/S0192415X21500373
46. d’Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front. Med. 2020;7:389. DOI: 10.3389/fmed.2020.00389
47. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95 (In Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95
48. Ertuzun I.A., Zueva E.P., Klylova S.G., Efimova L.A., Dugina Yu.L., Epstein O.I. Experimental study of preparation Kolofort — a novel drug for treatment of irritable bowel syndrome and other functional gastrointestinal disorders. Vestnik VolgGMU. 2012;4(44):25–27 (In Russ.).
49. Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A., Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol. 2019;20(1):2. DOI: 10.1186/s12876-019-1143-5
Supplementary files
Review
For citations:
Akhmedov V.A. COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):85-92. https://doi.org/10.22416/1382-4376-2022-32-2-85-92
Views:
1039
Email this article 
